Motoi Kuwahara
Overview
Explore the profile of Motoi Kuwahara including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
48
Citations
414
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Miyamoto K, Murakami K, Sakata M, Nakayama Y, Kuwahara M, Inoue N
Mult Scler Relat Disord
. 2025 Jan;
94:106282.
PMID: 39864318
Background: Biomarkers that predict disease activity and prognosis should be established for neuromyelitis optica spectrum disorders (NMOSD). In this study, we investigated the association between complement factors and the prognosis...
2.
Kojita Y, Kono A, Yamada T, Yamada M, Im S, Kozuka T, et al.
Neuroradiology
. 2024 Aug;
66(11):1887-1891.
PMID: 39207553
Symmetrical lesions in the temporal poles and external capsules on brain MRI are known as radiological markers of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL); however, similar...
3.
Kojita Y, Kono A, Yamada T, Yamada M, Im S, Kozuka T, et al.
Eur J Radiol
. 2024 Jul;
178:111597.
PMID: 38996736
Purpose: Multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) are two major demyelinating diseases affecting the central nervous system (CNS). The objective of this study is to evaluate the...
4.
Kuwabara S, Kusunoki S, Kuwahara M, Yamano Y, Nishida Y, Ishida H, et al.
J Peripher Nerv Syst
. 2024 Jul;
29(3):339-349.
PMID: 38987228
Background And Aims: Guillain-Barré syndrome (GBS) is an acute, self-limited, immune-mediated peripheral neuropathy. Current treatments for GBS include intravenous immunoglobulin (IVIg) and plasma exchange, which may not sufficiently benefit severely...
5.
Kuwahara M
Brain Nerve
. 2024 May;
76(5):540-546.
PMID: 38741494
Anti-myelin-associated glycoprotein (MAG) neuropathy, which occurs secondary to immunoglobulin (Ig)M paraproteinemia such as monoclonal gammopathy of undetermined significance, is characterized by slow progression, sensory or sensorimotor disturbances, and ataxia. The...
6.
Terayama A, Kuwahara M, Yoshikawa K, Yamagishi Y, Samukawa M, Yamashita S, et al.
J Neurol
. 2024 Apr;
271(7):4067-4074.
PMID: 38573364
Background And Purpose: Takotsubo cardiomyopathy (TCM) is a serious autonomic complication of Guillain-Barré syndrome (GBS). However, the association between TCM and GBS has not been investigated in detail. We investigated...
7.
Kuwahara M
Rinsho Shinkeigaku
. 2023 Dec;
64(1):1-7.
PMID: 38072443
The efficacy of immunotherapies such as steroids, plasmapheresis, and intravenous immunoglobulin have been proven in various immune-mediated neuropathies. However, these treatments sometimes lack the efficacy in a part of patients...
8.
Hirano M, Kuwahara M, Yamagishi Y, Samukawa M, Fujii K, Yamashita S, et al.
Sci Rep
. 2023 Oct;
13(1):17801.
PMID: 37853169
Cerebellar ataxia, neuropathy, and vestibular areflexia syndrome (CANVAS) has recently been attributed to biallelic repeat expansions in RFC1. More recently, the disease entity has expanded to atypical phenotypes, including chronic...
9.
Moriguchi K, Nakamura Y, Park A, Sato F, Kuwahara M, Khadka S, et al.
Int J Mol Sci
. 2023 Aug;
24(16).
PMID: 37629117
Anti-glycolipid antibodies have been reported to play pathogenic roles in peripheral inflammatory neuropathies, such as Guillain-Barré syndrome. On the other hand, the role in multiple sclerosis (MS), inflammatory demyelinating disease...
10.
Miyamoto K, Minamino M, Kuwahara M, Tsujimoto H, Ohtani K, Wakamiya N, et al.
Front Immunol
. 2023 Mar;
14:1090548.
PMID: 36936980
Complement is involved in the pathogenesis of neuroimmune disease, but the detailed pathological roles of the complement pathway remain incompletely understood. Recently, eculizumab, a humanized anti-C5 monoclonal antibody, has been...